Naftin

Naftifine Hydrochloride


Sebela Pharmaceuticals Inc.
Human Prescription Drug
NDC 54766-770
Naftin also known as Naftifine Hydrochloride is a human prescription drug labeled by 'Sebela Pharmaceuticals Inc.'. National Drug Code (NDC) number for Naftin is 54766-770. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Naftin drug includes Naftifine Hydrochloride - 10 mg/g . The currest status of Naftin drug is Active.

Drug Information:

Drug NDC: 54766-770
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Naftin
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Naftifine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Sebela Pharmaceuticals Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Gel
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:NAFTIFINE HYDROCHLORIDE - 10 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 22 Jan, 2018
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 28 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA019356
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Sebela Pharmaceuticals Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:896106
896108
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0354766770401
UPC stands for Universal Product Code.
UNII:25UR9N9041
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Allylamine Antifungal [EPC]
Allylamine [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
54766-770-401 TUBE in 1 CARTON (54766-770-40) / 40 g in 1 TUBE22 Jan, 2018N/ANo
54766-770-601 TUBE in 1 CARTON (54766-770-60) / 60 g in 1 TUBE22 Jan, 2018N/ANo
54766-770-901 TUBE in 1 CARTON (54766-770-90) / 90 g in 1 TUBE22 Jan, 2018N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Naftin naftifine hydrochloride alcohol water edetate disodium carbomer homopolymer type b (allyl sucrose crosslinked) polysorbate 80 diisopropanolamine naftifine hydrochloride naftifine

Indications and Usage:

Indications and usage naftin ® gel, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms trichophyton rubrum, trichophyton mentagrophytes, trichophyton tonsurans * efficacy for this organism in this organ system was studied in fewer than 10 infections. , epidermophyton floccosum * .

Warnings:

Warnings naftin ® gel, 1% is for topical use only and not for ophthalmic use.

General Precautions:

General naftin ® gel, 1%, is for external use only. if irritation or sensitivity develops with the use of naftin ® gel, 1%, treatment should be discontinued and appropriate therapy instituted. diagnosis of the disease should be confirmed either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium.

Dosage and Administration:

Dosage and administration a sufficient quantity of naftin ® gel, 1% should be gently massaged into the affected and surrounding skin areas twice a day, in the morning and evening. the hands should be washed after application. if no clinical improvement is seen after four weeks of treatment with naftin ® gel, 1%, the patient should be re-evaluated.

Contraindications:

Contraindications naftin ® gel, 1% is contraindicated in individuals who have shown hypersensitivity to any of its components.

Adverse Reactions:

Adverse reactions during clinical trials with naftin ® gel, 1%. the incidence of adverse reactions was as follows: burning/stinging (5.0%), itching (1.0%), erythema (0.5%), rash (0.5%), skin tenderness (0.5%).

Use in Pregnancy:

Pregnancy teratogenic effects reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Pediatric Use:

Pediatric use safety and effectiveness in pediatric patients have not been established.

Description:

Description naftin ® gel, 1% contains the synthetic, broad-spectrum, antifungal agent naftifine hydrochloride. naftin ® gel, 1% is for topical use only. chemical name (e)-n-cinnamyl-n-methyl-1-naphthalenemethylamine hydrochloride. naftifine hydrochloride has an empirical formula of c 21 h 21 n•hcl and a molecular weight of 323.86. chemical structure contains active ingredient naftifine hydrochloride 1%. inactive ingredients naftin ® gel, 1% contains polysorbate 80, carbomer 934p, diisopropanolamine, edetate disodium, alcohol (52%v/v), and purified water.

Clinical Pharmacology:

Clinical pharmacology naftifine hydrochloride is a synthetic allylamine derivative. the following in vitro data are available but their clinical significance is unknown. naftifine hydrochloride has been shown to exhibit fungicidal activity in vitro against a broad spectrum of organisms, including trichophyton rubrum, trichophyton mentagrophytes, trichophyton tonsurans, epidermophyton floccosum, microsporum canis, microsporum audouini, and microsporum gypseum, and fungistatic activity against candida species, including candida albicans. naftin ® gel, 1% has only been shown to be clinically effective against the disease entities listed in the indications and usage section. although the exact mechanism of action against fungi is not known, naftifine hydrochloride appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2, 3-epoxidase. this inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulatio
n of squalene in the cells. pharmacokinetics in vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes. following single topical applications of 3 h- labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed. naftifine and/or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days.

Pharmacokinetics:

Pharmacokinetics in vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes. following single topical applications of 3 h- labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed. naftifine and/or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility in a 2-year dermal carcinogenicity study, naftifine hydrochloride cream was administered to sprague-dawley rats at topical doses of 1%, 2% and 3% (10, 20, and 30 mg/kg/day naftifine hydrochloride). no drug-related tumors were noted in this study up to the highest dose evaluated in this study of 30 mg/kg/day [3.6 times the maximum recommended human dose (mrhd) based on mg/m2 comparison]. naftifine hydrochloride revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (ames assay and chinese hamster ovary cell chromosome aberration assay) and one in vivo genotoxicity test (mouse bone marrow micronucleus assay). oral administration of naftifine hydrochloride to rats, throughout mating, gestation, parturition and lactation, demonstrated no effects on growth, fertility or reproduction, at doses up to 100 mg/kg/day (12 times mrhd based on mg/m 2 comparison).

How Supplied:

How supplied naftin ® (naftifine hydrochloride) gel, 1% is supplied in collapsible tubes in the following sizes 40g – ndc 54766-770-40 60g – ndc 54766-770-60 90g – ndc 54766-770-90 note: store naftin ® gel, 1% at room temperature.

Information for Patients:

Information for patients the patient should be told to: avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician. keep naftin ® gel, 1% away from the eyes, nose, mouth and other mucous membranes.

Package Label Principal Display Panel:

Principal display panel - 40g tube carton ndc 54766-770-40 naftin ® 40g gel naftifine hcl 1% gel rx only 40g carton

Principal display panel - 60g tube carton ndc 54766-770-60 naftin ® 60g gel naftifine hcl 1% gel rx only 60g carton

Principal display panel - 90g tube carton ndc 54766-770-90 naftin ® 90g gel naftifine hcl 1% gel rx only 90g carton


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.